Researcher
Jan Cools
- Disciplines (Flanders Institute for Biotechnology):Analysis of next-generation sequence data, Cell death, Cancer biology
- Disciplines (KU Leuven):Hematology, Cancer biology
- See also: Cools J (Flanders Institute for Biotechnology)
Affiliations
- Laboratory of Molecular Biology of Leukemia (VIB-KU Leuven) (Division)
Responsible
From1 Jan 2008 → Today - Laboratory of Molecular Biology of Leukemia (VIB-KU Leuven) (Division)
Member
From1 Dec 2017 → Today - Cools Lab (Research group)
Responsible
From1 Jan 2017 → Today - Faculty of Medicine (Faculty)
Member
From1 Oct 2004 → 30 Sep 2005 - Department of Human Genetics (Department)
Member
From1 Oct 1999 → 30 Nov 2017
Projects
1 - 10 of 62
- Molecular characterization of hyperactive T cell receptor signaling in peripheral T cell lymphoma to uncover druggable targetsFrom2 Oct 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Molecular characterization of genetic events driving development of peripheral T cell lymphomaFrom2 Oct 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- GAINING INSIGHT IN THE MUTATIONAL PROFILE OF PT-DLBCL AND ASSESSING ITS BIOLOGICAL EFFECTS AND TRANSFORMING POTENTIALFrom2 Oct 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Degradation of CDK1 and HDACs as a strategy to treat T-cell malignanciesFrom1 Oct 2023 → TodayFunding: BOF - projects
- Uncovering mechanisms of TLX1/TLX3 oncogenic cooperation in leukemiaFrom1 Oct 2023 → TodayFunding: FWO senior postdoctoral fellowship
- EZH2 as a transcriptional activator in T-ALLFrom1 Jan 2023 → TodayFunding: Foundations, funds and other with scientific goal
- TLX transcriptional complexes in T-cell acute lymphoblastic leukemiaFrom1 Jan 2023 → TodayFunding: FWO research project (including WEAVE projects)
- Deregulated mRNA transcription and protein translation in the transformation of normal T-cells to malignant cells.From1 Jan 2023 → TodayFunding: BOF - iBOF
- Mechanisms of resistance to current treatment of acute myeloid leukemiaFrom15 Sep 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Oncogene cooperation enhancing TLX1 positive leukemia developmentFrom1 Sep 2022 → TodayFunding: Other federal public and semi-governmental institutions
Publications
181 - 190 of 200
- Identification and characterization of oncogenic tyrosine kinases and tyrosine kinase inhibitors(2009)
Authors: Els Lierman, Jan Cools, Peter Marynen
- FIP1L1-PDGFR alpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFR alpha T674I eosinophilic leukemia with single agent sorafenib(2009)
Authors: Lucienne Michaux, Peter Marynen, Jan Cools, Peter Vandenberghe
Pages: 845 - 851 - JAK1 mutation analysis in T-cell acute lymphoblastic leukemia cell lines(2009)
Authors: Michaël Porcu, Jan Cools, Kim De Keersmaecker
Pages: 435 - 437 - Atonal homolog 1 is a tumor suppressor gene.(2009)
Authors: Wouter Bossuyt, A Kazanjian, Natalie De Geest, S Van Kelst, Gert De Hertogh, Karel Geboes, GP Boivin, J Luciani, F Fuks, Marinee Chuah, et al.
Pages: 311 - 326 - Atonal homolog 1 is a tumor suppressor gene(2009)
Authors: Wouter Bossuyt, Natalie De Geest, Gert De Hertogh, Karel Geboes, Marinee Chuah, Thierry Vandendriessche, Peter Marynen, Jan Cools, Bassem Hassan
Pages: 311 - 326 - Heterogeneous patterns of amplification of the NUP214-ABL1 fusion gene in T-cell acute lymphoblastic leukemia(2009)
Authors: Carlos Graux, Annelies Simons, Lucienne Michaux, Peter Vandenberghe, Kim De Keersmaecker, Jan Cools
Pages: 125 - 133 - Intrinsic differences between the catalytic properties of the oncogenic NUP214-ABL1 and BCR-ABL1 fusion protein kinases(2008)
Authors: Kim De Keersmaecker, Jan Cools
Pages: 2208 - 2216 - Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells(2008)
Authors: Jan Cools
Pages: 5161 - 5170 - Evaluation of the Role of PIGF and the Therapeutic Potential of Anti-PIGF in BCR/ABL plus Leukemia(2008)
Authors: Sonja Loges, Thomas Schmidt, Ria Kleppe, Kim De Keersmaecker, Marc Tjwa, Christa Maes, Christiane DeWolf-Peeters, Peter Carmeliet, Jan Cools, Jean-Marie Stassen, et al.
Pages: 399 - 400 - FIP1L1-PDGFR alpha D842V, a Novel Panresistant Mutant, Emerges after Treatment of FIP1L1-PDGFR alpha T674I Eosinophilic Leukemia with Single Agent Sorafenib(2008)
Authors: Peter Vandenberghe, Els Lierman, Lucienne Michaux, Pascal Pierre, Peter Marynen, Jan Cools
Pages: 1279 - 1279
Patents
1 - 2 of 2